Today Baymatob™ welcomes the formal appointment of David O'Reilly to the Board of Directors. Possessing a wealth of experience across both the MedTech and pharmaceutical space, including women's health, David brings a strong skillsets to support and work with Baymatob as we implement our clinical and commercial strategies, and build on our momentum towards bringing our first product to market based upon our growing and compelling body of clinical evidence.
David joins Tony Barclay, Alwyn Reynolds and Sarah McDonald as a directors of Baymatob. We are excited to welcome him to the team and look forward to working together towards achieving our vision of transforming health outcomes for mothers and their babies, by leveraging our platform technology, Oli™.
David O’Reilly is an entrepreneur and executive in the life sciences industry with 30 years of experience in founding, financing and growing innovative pharmaceutical, medical device and digital health companies. He is co-founder and Chief Executive Officer of Cavalon Therapeutics, a company developing medicines for neurodegenerative and neuropsychiatric disorders. He is also Managing Director of Bayview Biosciences, a firm that provides advisory, consulting and new company formation services to life sciences organizations. Prior to this, David was Chief Platform Officer and Chief Product Officer of Proteus Digital Health, where he led Proteus’s sensor development, digital medicine formulation, product development, manufacturing operations and corporate development functions. Leading these teams, he negotiated and raised over $400 million in equity investments and strategic partner funding, launched three commercial digital medicine products, manufactured and shipped over 10 million product units annually and generated and managed over $30 million in revenue annually. Prior to Proteus, he was President of Catalyst Biosciences, Chief Business Officer of Iconix Biosciences, Head of Corporate Development at ARIAD Pharmaceuticals and a strategy consultant at L.E.K. Consulting. David also serves on the advisory boards of HealthRhythms, a digital therapeutics company, and Paradromics, a brain-computer interface company.